RECRUITINGOBSERVATIONAL
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study
About This Trial
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.
Who May Be Eligible (Plain English)
Who May Qualify:
- Histologically-confirmed stage II-IIIA or selected IIIB (T3N2) NSCLC as per the American Joint Committee on Cancer and International Union Against Cancer (UICC/AJCC), 8th edition
- ALK positive
- Postoperative NSCLC patients who have undergone complete resection
- Had taken Alectinib monotherapy without previous cancer treatment that works throughout the body (like chemotherapy) (including other ALK-TKIs or chemotherapy) as adjuvant† therapy for resected stage II-IIIB ALKpositive NSCLC and the time from the first dose to enrollment was no more than 28 days
Who Should NOT Join This Trial:
- Patients participating in interventional study of adjuvant treatment
- Pregnant, lactating, or breastfeeding women
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Histologically-confirmed stage II-IIIA or selected IIIB (T3N2) NSCLC as per the American Joint Committee on Cancer and International Union Against Cancer (UICC/AJCC), 8th edition
* ALK positive
* Postoperative NSCLC patients who have undergone complete resection
* Had taken Alectinib monotherapy without prior systemic therapy (including other ALK-TKIs or chemotherapy) as adjuvant† therapy for resected stage II-IIIB ALKpositive NSCLC and the time from the first dose to enrollment was no more than 28 days
Exclusion Criteria:
* Patients participating in interventional study of adjuvant treatment
* Pregnant, lactating, or breastfeeding women
Treatments Being Tested
DRUG
Alectinib
Participants will have received alectinib adjuvant treatment for resected stage II-IIIB ALK-positive NSCLC in routine clinical practice. NOTE: No intervention will be provided in this study as the study is observational.
Locations (20)
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangzhou, China
Huai He Hospital of Henan University
Kaifeng, Henan, China
Henan Provincial Chest Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Peking University First Hospital
Beijing, China
Xuanwu Hospital, Capital Medical University
Beijing, China
Changzhou First People's Hospital
Changzhou, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, China
The First Affiliated Hospital, Chongqing Medical University
Chongqing, China
The Second Affiliated Hospital of Dalian Medical University
Dalian, China
Fujian Cancer Hospital
Fuzhou, China
The Third Affiliated Hospital of Sun Yat-Sen University
Guangzhou, China
The Second Affiliated Hospital, Zhejiang University
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Anhui Provincial Hospital
Hefei, China
Huzhou Central Hospital
Huzhou, China
Jiangmen Central Hospital
Jiangmen, China
Shandong Provincial Hospital
Jinan, China